qxd 18 2 04 3:58 PM Page 1 AstraZeneca Annual Report and Cross Reference to Form 20-F Form 20-F Information 2003 Cross Reference to Form 20-F The information in this document that is referenced on this page is included in AstraZenecas Form 20-F for 2003 2003 Form 20-F and is filed with the Securities and Exchange Commission SEC.
The 2003 Form 20-F is the only document intended to be incorporated by reference into any filings by AstraZeneca under the Securities Act of 1933, as amended.
References to major headings include all information under such major headings, including subheadings.
References to subheadings include only the information contained under such subheadings.
Graphs are not included unless specifically identified.
The 2003 Form 20-F has not been approved or disapproved by the SEC nor has the SEC passed comment upon the accuracy or adequacy of the 2003 Form 20-F.
The 2003 Form 20-F filed with the SEC may contain modified information and may be updated from time to time.
Item Page Item Page 3 Key Information 9 The Offer and Listing A.
Price history of stock listed Financial Highlights 5 Shareholder Information 127 Group Financial Record 124 C. Markets Shareholder Information 127 Shareholder Information 128 D. Risk factors 135 10 Additional Information 4 Information on the Company B.
Memorandum and Articles of Association 140 A.
History and development of the Company 140 C. Material contracts n a Financial Review Investments, divestments D. Exchange controls 132 and capital expenditure 34 E. Taxation 131 Note 9 Tangible fixed assets 77 H. Documents on display 130 Note 24 Acquisitions of subsidiaries and I.
Subsidiary information 112 purchases of minority interests 87 Note 25 Disposals of business operations 88 11 Quantitative and Qualitative Disclosures B.
Business overview about Market Risk Operational Review 9 Financial Policies Treasury 35 C. Organisational structure Directors Report 43 12 Description of Securities other than Principal Subsidiaries 112 Equity Securities n a D. Property, plant and equipment Operational Review Main Facilities 28 13 Defaults, Dividend Arrearages and Delinquencies n a 5 Operating and Financial Review and Prospects A-F. Financial Review 31 14 Material Modifications to the Rights of Security Holders and Use of Proceeds n a 6 Directors, Senior Management and Employees A.
Directors and senior management 15 Controls and Procedures Board of Directors and Officers of the Company 6 Directors Report Internal Controls and B.
Compensation Management of Risk 45 Directors Remuneration Report 50 C. Board practices 16 [Reserved] Board of Directors and Officers of the Company 6 Directors Remuneration Report 50 A.
Audit committee financial expert Directors Report 43 Audit Committees Report 48 Audit Committees Report 48 B.
Code of ethics D. Employees Directors Report Code of Conduct 46 Note 30 Employee costs and share option C. Principal accountant fees and services plans for employees 95 Note 33 Statutory and other information 107 Directors Report Employees 47 D. Exemptions from the listing standards E. Share ownership for audit committees n a Directors Remuneration Report Directors Interests in Shares 57 18 Financial Statements Financial Statements excluding Directors 7 Major Shareholders and Related Party Transactions responsibilities on page 60 and Auditors A.
Major shareholders opinion on page 61 62 Shareholder Information Major shareholdings 129 B.
Related party transactions Shareholder Information Related party transactions 130 Note 33 Statutory and other information 107 8 Financial Information A.
Consolidated statements and other financial information Financial Statements excluding Directors responsibilities on page 60 and Auditors opinion on page 61 62 B.
